关于广西河池化工股份有限公司 2024 年度营业收入扣除事项的专项核查意见 中兴财光华审专字（2025）第 226015 号 目 录 关于广西河池化工股份有限公司 2024 年度营 业收入扣除事项的专项核查意见 广西河池化工股份有限公司 2024 年度营业收 入扣除情况表 我们的责任是在执行核查工作的基础上对营业收入扣除情况表发表专项 核查意见。我们按照中国注册会计师审计准则的规定执行核查工作。中国注 册会计师审计准则要求我们遵守中国注册会计师职业道德守则，计划和执行 核查工作，以对营业收入扣除情况表是否不存在重大错报获取合理保证。在 核查过程中，我们实施了包括检查会计记录等我们认为必要的程序。我们相 信，我们的核查工作为发表意见提供了合理的基础。 三、专项核查意见 关于广西河池化工股份有限公司 2024 年度营业收入扣除事项的专项核查意见 中兴财光华审专字（2025）第 226015 号 广西河池化工股份有限公司全体股东： 我们接受委托，对广西河池化工股份有限公司（以下简称"河化股份"） 2024 年度财务报表进行审计，并出具了中兴财光华审会字（2025）第 226015 号审计报告。在此基础上，我们对河化 ...

目录 审计报告 | 合并及公司资产负债表 | 1-2 | | --- | --- | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并及公司股东权益变动表 | 5-8 | | 财务报表附注 | 9-105 | 广西河池化工股份有限公司 中兴财光华审会字（2025）第 226015 号 审计报告 中兴财光华审会字(2025)第 226015 号 广西河池化工股份有限公司全体股东： 一、审计意见 我们审计了广西河池化工股份有限公司（以下简称"河化股份"）财务报 表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司 利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财务报表附 注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了河化股份 2024 年 12 月 31 日的合并及公司财务状况以及 2024 年 度的合并及公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的 "注册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的 责任。 ...

2025 年 4 月 24 日 经核查独立董事郭益浩先生、薛有冰先生、李洪仪先生的任职经历以及签 署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系 或其他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》中对独立董事独立性的相关要求。 广西河池化工股份有限公司董事会 广西河池化工股份有限公司董事会 关于独立董事 2024 年度独立性情况的专项意见 根据证监会《上市公司独立董事管理办法》《深圳证券交易所股票上市规 则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等要求，广西河池化工股份有限公司（以下简称"公司"）董事会，就公 司独立董事郭益浩先生、薛有冰先生、李洪仪先生在 2024 年度任职的独立性 情况进行评估并出具如下专项意见： ...

广西河池化工股份有限公司 2024 年度独立董事述职报告 （郭益浩） 二、独立董事年度履职情况 作为广西河池化工股份有限公司(以下简称"公司")的独立董事，2024 年 度我严格按照《公司法》《上市公司治理准则》和《上市公司独立董事管理办法》 等法律法规以及《公司章程》的规定，忠实履行独立董事职责，不受公司大股东、 实际控制人或者其他与公司存在利益关系的单位与个人的影响，积极出席公司股 东大会和董事会，对公司的生产经营和业务发展提出合理的建议，充分发挥了独 立董事作用，维护公司股东的合法权益。现将我于 2024 年度工作情况作如下报 告： （一）出席会议情况 一、独立董事的基本情况 郭益浩：本科学历，中国注册会计师、注册税务师、高级会计师。中国国籍， 无境外居留权。历任广西会计师事务所审计员、部门经理、副所长，上海东华会 计师事务所有限公司副主任会计师兼广西分所所长，瑞华会计师事务所（特殊普 通合伙）广西分所合伙人、所长。现任致同会计师事务所（特殊普通合伙）广西 分所合伙人、所长，本公司独立董事。 公司 2024 年度共计召开 2 次股东大会，6 次董事会，本人出席情况如下： 报告期内，本人任职符合《上市公司 ...

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2200 | -0.0300 | 833.33 | -0.2700 | | 每股净资产（元） | 0.4 | 0.18 | 122.22 | 0.21 | | 每股公积金(元) | 1.38 | 1.38 | 0 | 1.38 | | 每股未分配利润(元) | -2.02 | -2.24 | 9.82 | -2.20 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.12 | 1.87 | 13.37 | 1.61 | | 净利润(亿元) | 0.79 | -0.12 | 758.33 | -1 | | 净资产收益率(%) | 74.13 | -16.01 | 563.02 | -78.69 | 不分配不转增 前十大流通股东累计持有： 14532.69万股，累计占流通 ...

Financial Performance - The company's operating revenue for 2024 was CNY 211,517,959.76, representing a 12.81% increase compared to CNY 187,495,292.44 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 79,252,735.53, a significant increase of 785.62% from a loss of CNY 11,559,209.01 in 2023[22]. - The net profit after deducting non-recurring gains and losses was CNY 3,890,421.44, up 132.35% from a loss of CNY 12,026,918.75 in the previous year[22]. - The basic earnings per share for 2024 was CNY 0.22, compared to a loss of CNY 0.03 per share in 2023, marking an increase of 833.33%[22]. - The total assets at the end of 2024 were CNY 332,938,240.48, an 18.38% increase from CNY 281,233,757.18 at the end of 2023[22]. - The net assets attributable to shareholders increased by 117.78% to CNY 145,039,259.79 at the end of 2024, up from CNY 66,599,087.68 in 2023[22]. - The company reported a negative net cash flow from operating activities of CNY -28,040,184.46, a decline of 234.00% compared to CNY 20,925,407.23 in 2023[22]. - The weighted average return on net assets for 2024 was 74.13%, a significant improvement from -16.01% in 2023[22]. Revenue Breakdown - In Q1 2024, the company reported a revenue of ¥61,917,759.50, which increased to ¥66,420,747.03 in Q2, but dropped to ¥38,356,605.32 in Q3, and rebounded to ¥44,822,847.91 in Q4[26]. - The company achieved a 49.12% year-on-year increase in domestic revenue, effectively offsetting a 28.81% decline in export revenue[50]. - The company's total revenue reached 21,151.80 million yuan, representing a 12.81% year-on-year growth, with net profit attributable to shareholders increasing by 785.62% to 7,925.27 million yuan[53]. - The chemical industry contributed ¥117,913,785.29, a 21.44% increase from ¥97,095,557.36 in 2023, accounting for 55.75% of total revenue[55]. - Domestic sales amounted to ¥184,355,421.98, up 23.45% from ¥149,340,003.56 in 2023, representing 87.16% of total revenue[55]. - The CDMO segment's revenue surged by 127% to 21,200,000 yuan, with gross profit turning from loss to profit due to cost reductions exceeding 20%[51]. Market and Product Development - The pharmaceutical intermediates market is experiencing a recovery with increasing demand due to the growth of new treatment fields like gene and cell therapy[30]. - The company emphasizes R&D in new products and has established a dedicated project management system to enhance production efficiency and reduce costs[34]. - The company has a flexible production model that allows for customized production based on client specifications, catering to diverse customer needs[37]. - The sales strategy includes direct engagement with clients through various channels, ensuring a stable supply of high-quality products[38]. - The company plans to expand its product supply chain and increase market space and marginal benefits in 2025[88]. - The company aims to enhance management efficiency and reduce procurement costs through refined and streamlined management practices[89]. - The company will increase R&D investment and focus on introducing CDMO projects to develop new products and improve profitability[89]. Risk Management and Governance - The company has outlined potential risks and countermeasures in its future development outlook section[5]. - The company faces risks from the "volume-based procurement" policy, which may lead to significant price reductions for drugs, impacting the pricing structure of its products[90]. - The company’s export revenue is primarily settled in foreign currencies, making it vulnerable to exchange rate fluctuations that could affect its price competitiveness[90]. - The company has established a value management system and is implementing a valuation enhancement plan to improve its market standing[94]. - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations during shareholder meetings[97]. - The company maintains independence from its controlling shareholder, ensuring that major decisions are made in accordance with established procedures[98]. - The company has a robust risk control mechanism in place to enhance its governance level and ensure compliance with evolving regulations[104]. Environmental and Social Responsibility - The company emphasizes the protection of shareholder rights, ensuring timely and accurate information disclosure through various channels[156]. - Employee welfare includes housing, transportation, and meals, along with regular health checks and training programs[157]. - The company has increased investment in environmental protection facilities and improved production processes to enhance energy efficiency and reduce emissions[159]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[150]. - The total discharge of COD was reported at 3.13 tons, with a concentration of 66 mg/L, complying with the wastewater discharge standards[151]. - The company paid an environmental protection tax of 15,597.74 yuan in 2024[154]. Management and Compensation - The total pre-tax compensation of the current general manager, Jiang Luben, was reported at 25.85 million yuan[129]. - The total compensation for the company's board members and senior management during the reporting period amounted to 172.2 million yuan[130]. - The company has a performance-based bonus system for senior management, which is approved by the board of directors[128]. - The company has a total of 12 individuals in key management positions, with varying roles and compensation structures[129]. - The board of directors held multiple meetings during the reporting period, with significant resolutions including the approval of the 2023 annual financial report and the proposal for profit distribution[131]. Strategic Outlook - The company plans to hold its annual general meeting and has proposed changes to the management structure, including the appointment of a new general manager[131]. - The company is preparing for a share buyback program through centralized bidding, reflecting confidence in its financial position[131]. - The company is focusing on enhancing its digital transformation strategy to improve operational efficiency by 25% by 2025[113]. - The company plans to enhance its supply chain efficiency, aiming for a 15% reduction in operational costs by the end of the fiscal year[116]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million CNY allocated for potential deals[116].

维生素概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002562 | 兄弟科 技 | 5.98 | 20.69 | 19239.70 | 28.35 | | 300267 | 尔康制 药 | 20.00 | 9.08 | 12096.35 | 31.77 | | 000953 | 河化股 份 | 10.02 | 6.79 | 7380.23 | 48.73 | | 300765 | 新诺威 | -1.83 | 1.78 | 6746.74 | 7.09 | | 002365 | 永安药 业 | 10.04 | 20.45 | 5359.70 | 8.87 | | 600129 | 太极集 团 | 3.14 | 3.64 | 3499.85 | 8.21 | | 600298 | 安琪酵 | 2.79 | 1.31 | 2388.41 | 6.33 | | 603676 | 卫信康 | 8.78 | 5. ...

截至4月24日收盘，CRO概念上涨0.96%，位居概念板块涨幅第9，板块内，38股上涨，金凯生科20%涨 停，双成药业、河化股份、凯莱英等涨停，峆一药业、博腾股份、昊帆生物等涨幅居前，分别上涨 6.50%、5.35%、4.50%。跌幅居前的有星昊医药、康鹏科技、蔚蓝生物等，分别下跌8.43%、4.30%、 3.46%。 今日涨跌幅居前的概念板块 | 业 | | --- | | 603259 | 药明康 | 0.36 | 1.49 | 2800.31 | 1.32 | | --- | --- | --- | --- | --- | --- | | | 德 | | | | | | 300363 | 博腾股 | 5.35 | 5.1 1 | 2230.39 | 5.99 | | | 份 | | | | | | 300725 | 药石科 | 0.38 | 4.14 | 1420.31 | 6.43 | | | 技 | | | | | | 300347 | 泰格医 | 0.35 | 1.99 | 1315.18 | 2.54 | | | 药 | | | | | | | 圣诺生 | | | | | | 688117 | ...

新股方面，今天A股市场有两只新股上市，悉数大幅上涨，其中新股江顺科技（001400）盘中涨幅一度超过120%。 港股市场盘中走低，不过仍有不少股票大涨，其中凯莱英（002821）港股盘中一度大涨超19%。 CXO、维生素、电力等板块逆市走强。 今天上午A股市场整体窄幅震荡，电力、CXO、维生素等概念板块走强。 A股市场窄幅震荡 今天上午A股市场整体窄幅震荡走低。截至午间收盘，上证指数跌0.1%，深证成指跌0.66%，北证50指数跌2.8%，创业 板指跌0.68%。 主要行业板块和赛道方面，日用化工、煤炭、造纸、农林牧渔等板块涨幅居前。软件服务、互联网、矿物制品、IT设 备等板块跌幅居前。 | 电力板块走强，华银电力（600744）、西昌电力（600505）、郴电国际（600969）等多股涨停，另有多股大幅上涨。 | | --- | | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 600744 | 华银电力 | 3.85 | 0.35 | 10.00% | | 600505 | 西昌电力 | 17.31 | 1.57 | 9.97% ...

Group 1 - The chemical pharmaceutical sector is experiencing a strong rebound, with significant stock price increases for companies such as Hehua Co., Ltd. (000953) and Lingkang Pharmaceutical (603669) reaching the daily limit [1] - Erkang Pharmaceutical (300267) has seen a nearly 10% increase in its stock price, indicating positive market sentiment [1] - Other companies like Luoxin Pharmaceutical (002793) and Yifang Bio are also experiencing notable price surges, reflecting a broader trend in the sector [1] Group 2 - There is a noticeable influx of dark pool funds into these stocks, suggesting increased investor interest and potential for further price movements [1]